Lifeward (NASDAQ:LFWD) versus TriSalus Life Sciences (NASDAQ:TLSIW) Critical Analysis

TriSalus Life Sciences (NASDAQ:TLSIW – Get Free Report) and Lifeward (NASDAQ:LFWD – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends.

Analyst Ratings

This is a summary of current ratings and price targets for TriSalus Life Sciences and Lifeward, as provided by MarketBeat.

Lifeward has a consensus target price of $10.00, suggesting a potential upside of 35.70%. Given Lifeward’s stronger consensus rating and higher possible upside, analysts clearly believe Lifeward is more favorable than TriSalus Life Sciences.

Profitability

This table compares TriSalus Life Sciences and Lifeward’s net margins, return on equity and return on assets.

Earnings & Valuation

This table compares TriSalus Life Sciences and Lifeward”s revenue, earnings per share and valuation.

TriSalus Life Sciences has higher revenue and earnings than Lifeward.

Insider & Institutional Ownership

26.8% of Lifeward shares are owned by institutional investors. 1.5% of Lifeward shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Lifeward beats TriSalus Life Sciences on 5 of the 9 factors compared between the two stocks.

About TriSalus Life Sciences

(Get Free Report)

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

About Lifeward

(Get Free Report)

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.